Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jun 7;45(22):1971-1987.
doi: 10.1093/eurheartj/ehae161.

Use of new and emerging cancer drugs: what the cardiologist needs to know

Iacopo Fabiani  1 , Michela Chianca  2 , Alberto Aimo  1   2 , Michele Emdin  1   2 , Susan Dent  3 , Antonella Fedele  4 , Carlo Maria Cipolla  4 , Daniela Maria Cardinale  4
Affiliations
Review

Use of new and emerging cancer drugs: what the cardiologist needs to know

Iacopo Fabiani et al. Eur Heart J. .

Abstract

The last decade has witnessed a paradigm shift in cancer therapy, from non-specific cytotoxic chemotherapies to agents targeting specific molecular mechanisms. Nonetheless, cardiovascular toxicity of cancer therapies remains an important concern. This is particularly relevant given the significant improvement in survival of solid and haematological cancers achieved in the last decades. Cardio-oncology is a subspecialty of medicine focusing on the identification and prevention of cancer therapy-related cardiovascular toxicity (CTR-CVT). This review will examine the new definition of CTR-CVT and guiding principles for baseline cardiovascular assessment and risk stratification before cancer therapy, providing take-home messages for non-specialized cardiologists.

Keywords: Cardio-oncology; Cardiotoxicity; Cardiovascular disease; Imaging; New cancer drugs; Target therapy.

PubMed Disclaimer

MeSH terms

Substances